LILRB4 and neoplasm: However, after treatment with an anti-LILRB4 antibody, mice show a significant reduction in tumor load and improved survival, suggesting that LILRB4 strongly suppresses tumor immunity in the tumor microenvironment and that this suppression can be attenuated by administering a monoclonal antibody against LILRB4 to provide effective antitumor therapy.